FDA Approves Sonidegib for Locally Advanced Basal Cell Carcinoma

July 27, 2015

The U.S. Food and Drug Administration (FDA) approved sonidegib for the treatment of locally advanced basal cell carcinoma. The drug is specifically approved for patients who saw a recurrence after surgery or radiation or for patients who are unable to receive surgery or radiation. The drug is taken orally. Read more here.

To learn more about basal cell carcinoma and treatments, visit My PearlPoint.